Top Anti Cancer Imported Medicine Drugs in India - Pharma Five

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Buy Anktiva (Nogapendekin alfa inbakicept-pmln) Medicine in India

Anktiva (Nogapendekin alfa inbakicept-pmln)

Medicine name : Anktiva

Generic name : Nogapendekin alfa inbakicept-pmln

Manufactured By : Altor BioScience, LLC (ImmunityBio)

Indications : Treatment of adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), including carcinoma in situ with or without papillary tumors and high-grade papillary-only tumors.

Medicine Description : An immunotherapy used with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Anktiva (Nogapendekin alfa inbakicept-pmln) stimulates immune cell activity to help the body recognise and attack bladder cancer cells.

Product Introduction

Anktiva (Nogapendekin Alfa Inbakicept-pmln) is an immunotherapy medicine used in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). Its approved indication includes carcinoma in situ (CIS), with or without papillary tumours, and high-grade papillary-only tumours. It belongs to a class of medicines called interleukin-15 (IL-15) receptor agonists, which stimulate immune cells to help recognise and destroy cancer cells.

Anktiva is administered directly into the bladder through a urinary catheter by a qualified healthcare professional. The recommended induction treatment is given once weekly for six weeks, followed by additional treatment according to the patient's response and prescribed maintenance schedule. Regular cystoscopy, urine tests and medical evaluations are important to assess treatment effectiveness.

Common side effects may include painful urination, blood in the urine, frequent urination, urinary urgency, urinary tract infections, increased creatinine, increased potassium, muscle or joint pain, chills and fever. Serious concerns include severe urinary infections, immune-related complications and the risk of bladder cancer progression if necessary surgery is delayed. Patients should promptly report fever, severe urinary symptoms, difficulty urinating or worsening blood in the urine.

Uses Of Anktiva (Nogapendekin alfa inbakicept-pmln)

Treatment of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)

Benefits Of Anktiva

Used in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive NMIBC, including carcinoma in situ (CIS) with or without papillary tumours and high-grade papillary-only tumours. It stimulates immune activity to help the body fight bladder cancer cells.

Side Effects Of Anktiva (Nogapendekin alfa inbakicept-pmln)

Some side effects of Anktiva (Nogapendekin Alfa Inbakicept-pmln) may occur when used with BCG. Inform your doctor if symptoms persist, worsen or become uncomfortable.

Common Side Effects of Anktiva (Nogapendekin alfa inbakicept-pmln)

  • Painful urination
  • Blood in the urine
  • Frequent urination
  • Sudden urge to urinate
  • Urinary tract infections
  • Muscle and joint pain
  • Chills
  • Fever
  • Fatigue
  • Nausea
How To Use Anktiva

Anktiva is administered directly into the bladder through a urinary catheter by a qualified healthcare professional, in combination with BCG. The recommended induction dose is 400 mcg once weekly for 6 weeks. Maintenance treatment is given according to the prescribed schedule, with regular bladder examinations to monitor response. It is for intravesical use only and must not be given by injection into a vein or muscle.

How Anktiva (Nogapendekin alfa inbakicept-pmln) Works

Anktiva is an interleukin-15 (IL-15) receptor agonist that stimulates the immune system. It activates natural killer (NK) cells, CD8+ T cells and memory T cells, helping the body recognise and attack bladder cancer cells. When combined with BCG, it enhances the immune response against cancer cells in the bladder.

Storage Conditions
  • Store unopened vials in a refrigerator between 2°C and 8°C.
  • Keep the vials in their original carton to protect them from light.
  • Do not freeze or shake the medicine.
  • If the prepared Anktiva and BCG mixture is not used immediately, refrigerate at 2°C to 8°C and use within 2 hours. Discard any unused mixture after 2 hours.
Safety Advice

AlcoholAlcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment. Avoid excessive drinking, particularly if you experience fever, fatigue or other treatment-related symptoms.

PregnancyPregnancy CONSULT YOUR DOCTOR

Anktiva may cause harm to an unborn baby. Avoid pregnancy during treatment and use effective contraception during treatment and for 1 week after the last dose.

BreastfeedingBreastfeeding CONSULT YOUR DOCTOR

Consult your doctor before breastfeeding during treatment. There is limited information about the presence of Anktiva in human breast milk and its effects on the baby.

DrivingDriving CONSULT YOUR DOCTOR

Anktiva is not expected to significantly affect driving ability. However, avoid driving if you experience fever, fatigue, dizziness or discomfort.

KidneyKidney CAUTION

Inform your doctor about existing kidney problems. Kidney function and creatinine levels may need regular monitoring during treatment.

LiverLiver CAUTION

Inform your doctor if you have liver disease. Report unusual symptoms such as yellowing of the skin or eyes, and follow your doctor's monitoring recommendations.

Quick Tips
  • Receive Anktiva directly into the bladder through a catheter under medical supervision.
  • Follow the prescribed BCG treatment and maintenance schedule carefully.
  • Attend regular cystoscopy examinations to monitor bladder cancer response.
  • Report fever, painful urination, blood in the urine or difficulty passing urine promptly.
  • Complete all scheduled follow-ups and inform your doctor about any persistent side effects.
  • Read More About - Anktiva (Nogapendekin alfa inbakicept-pmln) from Pharma Five.
About Pharma Five

Pharma Five assists patients seeking Anktiva (Nogapendekin Alfa Inbakicept-pmln) by helping facilitate the import of limited quantities for personal medical use, in accordance with applicable regulations. Depending on the requirements, Form 12A, a valid prescription from a Registered Medical Practitioner (RMP), and other supporting documents may be required.

With more than 20 years of pharmaceutical industry experience, Pharma Five provides specialised medicine consultancy and import assistance for patients requiring Anktiva (Nogapendekin Alfa Inbakicept-pmln). The team offers guidance on documentation and helps patients navigate the applicable medicine import procedures. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

References
  1. https://go.drugbank.com/drugs/DB18740
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf
  3. https://www.fda.gov/drugs/cancer-approvals/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle
  4. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eae31db8-3e7a-d9e0-708d-74419d1b50ff
Faq

General Question

Anktiva (Nogapendekin Alfa Inbakicept-pmln) is an immunotherapy medicine used with Bacillus Calmette-Guérin (BCG) to treat adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC).

Anktiva activates the interleukin-15 (IL-15) receptor pathway, stimulating immune cells such as natural killer cells and T cells to help the body fight bladder cancer.

Anktiva is prescribed for adults with BCG-unresponsive non-muscle-invasive bladder cancer. A specialist evaluates the cancer type, previous BCG treatment and overall health before recommending it.

Anktiva is administered directly into the bladder through a urinary catheter by a qualified healthcare professional, in combination with BCG. The prescribed treatment schedule and bladder-retention instructions must be followed.

Common side effects include increased creatinine, painful urination, blood in the urine, frequent urination, urinary urgency, urinary tract infection, increased potassium, muscle or joint pain, chills and fever.

Yes. Anktiva treatment requires monitoring for urinary complications and other adverse reactions. Delaying recommended bladder removal surgery when cancer persists may increase the risk of cancer spreading. Report prolonged urinary symptoms or blood in the urine to your doctor.

The treatment duration depends on the prescribed induction and maintenance schedule, treatment response and medical evaluation. Your specialist will determine whether additional treatment is appropriate.

Consult your doctor before consuming alcohol during treatment. Discuss alcohol use in relation to your overall health, other medicines and any treatment-related symptoms.

Anktiva may cause fetal harm if systemic exposure occurs. Pregnancy status should be checked before treatment, and females of reproductive potential should use effective contraception during treatment and for one week after the last dose.

Tell your doctor about all prescription medicines, over-the-counter products, vitamins and supplements you use. Your healthcare team can assess potential interactions and treatment-related risks.

If you miss a scheduled Anktiva treatment appointment, contact your doctor or treatment centre as soon as possible to arrange further instructions. Do not attempt to administer the medicine yourself.

Anktiva is administered directly into the bladder, not taken by mouth. It does not require oral food-related dosing instructions; follow your doctor's advice about your usual diet.

Attend all scheduled bladder examinations and follow-up appointments. Maintain adequate hydration after treatment, report prolonged urinary symptoms or red-coloured urine, and discuss any planned surgery with your specialist.

Store Anktiva vials in a refrigerator at 2°C to 8°C (36°F to 46°F), in the original carton to protect them from light. Do not freeze or shake the vials.

Pharma Five can provide guidance and assistance with accessing Anktiva through applicable medicine import procedures for personal medical use. Import is subject to regulatory requirements and the necessary medical documentation. Pharma Five assists in its procurement.

Timely Service
Doorstep Delivery
Hassle-Free Process
100% Genuine Sources